US Medicare begins new look at spinal disc coverage - MCAC panel reaches "benign" conclusions
This article was originally published in Clinica
US Medicare is taking a new look at whether it should pay for the use of artificial spinal discs for its 43 million members.
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.